Home World News FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for... World News FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 901 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Targeting FGFR1 in Patients with Tumour-Induced Osteomalacia September 16, 2020 Spectacular Breast Cancer Awareness Calendar Showcases Survivors’ Stories, Told with Body... October 17, 2019 Children’s Hospital Lets Kids Ride Toy Cars Into Surgery To Ease... June 19, 2019 ΠΟΝΟΣ March 8, 2019 Load more HOT NEWS No Clinically Meaningful Difference in Survival Between Nivolumab Plus Ipilimumab and... Ribociclib Approval Expanded for Some Women with Advanced Breast Cancer pCR Correlates with RFS and OS with Neoadjuvant Therapy in Stage... Initial Results of the CanScreen5, an Authentic Data Repository for Cancer...
